Trial Profile
Post Marketing Surveillance to Observe Safety of Prevenar 13.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2017
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 22 Jun 2016 Status changed from recruiting to completed.
- 15 Oct 2015 Status changed from active, no longer recruiting to recruiting, according to ClinicalTrials.gov record.
- 05 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.